Cavinton

Selected form

Vinpocetine

Method of action: Antihypoxic, Antioxidant, Antiplatelet, Neuroprotective, Nootropic, Psychoanaleptics, Vasodilator

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cavinton

Quick Facts

Property	Description
Active Ingredient	Vinpocetine (Ethyl apovincaminate)
Form	Tablet, Concentrate for solution for infusion
Pharmacological Class	Cerebrovasodilator, Nootropic agent
Common Use	Supports cerebral blood flow and neuronal metabolism
Origin	Semi-synthetic (derived from Vinca alkaloids)

Cavinton: Definition and Pharmacological Classification

Cavinton is a pharmaceutical preparation that utilizes the active ingredient Vinpocetine, which is a semi-synthetic derivative of the Vinca alkaloid vincamine. The chemical structure of Vinpocetine is based on compounds found in the Vinca minor plant (lesser periwinkle). This compound is clinically recognized for its pharmacological properties as both a cerebrovasodilator and a nootropic agent (cognitive enhancer). Cavinton is typically offered as a prescription-only medicine, underscoring its intended use under medical supervision. Its classification, confirmed by the Anatomical Therapeutic Chemical (ATC) code N06BX18, places it within medicines supporting nervous system function.

Vinpocetine: Forms, Composition, and General Purpose

Vinpocetine is marketed as a single-ingredient product, available to patients in two main dosage forms: the tablet for oral administration and the concentrate for solution for infusion designed for intravenous delivery. The availability of these forms, which includes the faster-acting injectable concentrate, provides distinct clinical routes for delivery. The overarching general purpose of the medication is to enhance the brain’s ability to receive and utilize vital resources. By selectively increasing cerebral blood flow and supporting neuronal metabolism, Cavinton is intended to promote the efficient delivery of oxygen and glucose to brain tissue, thereby supporting the functional efficiency of neurological systems.

What side effects are possible with Cavinton?

Possible Side Effects and Safety Information

The safety profile of Vinpocetine, the active ingredient in Cavinton, is based on official regulatory documentation that classifies adverse events and defines explicit constraints on its use. Adverse reactions are grouped by the affected physiological system and frequency of occurrence.

Adverse effects are documented primarily across several systems, including the Nervous System (e.g., headache, vertigo), Gastrointestinal System (e.g., nausea, abdominal pain), and Vascular System (e.g., mild reduction in blood pressure).

Frequency Classification	Examples of Documented Effects
Uncommon (1/1,000 to 1/100)	Headache, vertigo, mild hypotension, nausea, skin rash.
Rare (1/10,000 to 1/1,000)	Tachycardia, anxiety, abdominal pain, paresthesia.

Serious Regulatory Safety Findings

Official labeling documents a risk of QT interval prolongation, which involves the electrical activity of the heart. Additionally, regulatory authorities have identified serious safety constraints for specific populations. The medicine is contraindicated during pregnancy and lactation due to the documented risk of adverse reproductive effects, including miscarriage and fetal harm.

Safety-Related Restrictions

Absolute contraindications for the use of Vinpocetine include conditions such as recent cerebral hemorrhage and intracranial hypertension. Caution is required when administering the drug to patients with existing conditions like hepatic impairment or a history of prolonged QT interval. Furthermore, the regulatory documents note that the medication may impair a person's reaction capacity, which could affect the ability to drive or operate machinery.

Overdose and Emergency Response

The regulatory information concerning overdose for Cavinton (Vinpocetine) is defined by the absence of formally reported clinical cases. Official government-authorized prescribing information explicitly states that there have been no cases of overdose formally reported. Due to this finding, a specific, clinically documented overdose syndrome or set of manifestations is not described in regulatory labeling.

Furthermore, the official documentation highlights a degree of demonstrated tolerance to the compound, noting that adverse reactions did not occur even after the administration of single doses up to 360 mg, an amount six times greater than the typically recommended therapeutic daily dose.

Emergency Response and Management

Despite the absence of a defined clinical profile, regulators mandate strict emergency management procedures for any excessive ingestion. Immediate medical attention must be sought for any suspected overdose or following the ingestion of a dose significantly exceeding the prescribed amount.

Required Action: Seek immediate medical attention.
Mandated Management: Management must be strictly symptomatic and supportive. This procedural action is required to maintain vital functions and treat any clinical signs that might appear, even without established manifestations. Close hospital monitoring may be required.
Antidote Status: No specific antidote is known for Vinpocetine overdose.

Therapeutic Uses of Cavinton

Cavinton is commonly used to help with conditions characterized by impaired cerebral blood flow and the resulting neurological and cognitive symptoms. The drug may be part of symptomatic management across several key domains in cerebrovascular diseases.

The medication is relevant for easing symptoms associated with conditions such as vascular dementia, chronic cerebral ischemia, and post-stroke recovery, as well as certain neurosensory disturbances like vertigo and specific types of tinnitus. It is typically applied in clinical settings that involve acute or unstable symptom patterns, and is commonly used when short-term symptomatic assistance is needed.

Addressing Cognitive Symptoms and Neurosensory Disturbances

Cavinton is commonly used to help address symptom clusters that may become intense or disruptive, including difficulties with memory, concentration, and attention span. This supportive therapy contributes to easing symptoms that interfere with daily functioning and supports a sense of stability.

“This therapy is generally used for managing symptoms and supporting the patient during difficult episodes by easing distress.”

In the context of post-stroke management and chronic psycho-syndromes, it is applied to help address neurological deficits and associated emotional instability.

Quick Fact: Symptom Management for Cognitive and Neurosensory Issues
Symptom Category	Symptoms that create noticeable physiological strain
Use Context	Conditions characterized by periods of heightened symptoms (e.g., chronic cerebral ischemia)
Patient Benefit	Contributes to easing the overall symptom load and supports general well-being during symptomatic phases

Eligibility and Restrictions for Use

Official Population Eligibility Rules for Cavinton (Vinpocetine)

Official regulatory documents strictly define the populations permitted and prohibited from using Cavinton. The medicine is primarily established for use in adults (18 years and older).

Absolute Contraindications (Must NOT Use):

The medicine is strictly contraindicated and must not be used in patients with the following severe conditions, according to the official product labeling:

Acute phase of haemorrhagic cerebral bleeding (e.g., intracerebral hemorrhage).
Severe coronary heart disease or severe arrhythmia.
Known hypersensitivity to Vinpocetine or any tablet excipients (e.g., lactose in some formulations).

Age and Reproductive Exclusions:

Population Group	Eligibility Status (Regulatory Wording)
Pregnancy	Contraindicated
Breastfeeding	Contraindicated
Children/Adolescents (Under 18)	Contraindicated / Not recommended (Use not established)

Conditional Use and Special Precautions:

While generally not requiring adjustment, severe renal impairment may require a dose reduction. Use requires caution and monitoring in patients with a congenital or acquired prolonged QT interval due to potential cardiac effects.

What should I know about interactions with other medicines?

Cavinton Interactions with Other Medicines and Products

Official regulatory documents define the interaction profile of Cavinton (Vinpocetine) primarily by potential pharmacodynamic additive effects and specific pharmacokinetic constraints.

Interaction Type	Interacting Medicines / Class	Regulatory Constraint or Outcome
Additive Pharmacodynamic	Anticoagulants (e.g., Warfarin) and Antiplatelet Drugs	Increased documented risk of bruising and bleeding.
	Antihypertensive Agents (e.g., alpha-methylodopa)	Increased risk of low blood pressure (hypotension).
Pharmacokinetic / Metabolic	P-glycoprotein (P-gp) Substrates and CYP2C9 Substrates	Caution advised due to the potential for Vinpocetine to alter the exposure of these co-administered drugs.
Food Interaction	Food (Oral Tablets)	Oral tablets must be taken after a meal as food significantly increases absorption, which is a required administration condition.

Combinations requiring special procedural constraints include concurrent use with Warfarin, where regular monitoring of Prothrombin Time (INR) is mandated in the labeling. Furthermore, caution is recommended when used alongside CNS drugs and antiarrhythmic agents. The overall interaction profile establishes a set of procedural monitoring requirements and specific administration conditions written into the official prescribing information.

Mechanism of Action

How Cavinton Works

Cavinton's mechanism of action is defined by a dual approach that modulates cerebral hemodynamics and influences neuronal energy metabolism within the central nervous system. The active ingredient, Vinpocetine, exerts its effects across distinct biochemical pathways that regulate cerebral vasculature and neuronal function.

Selective Modulation of cGMP Signaling

This domain involves the drug's primary action as a selective inhibitor of the enzyme cGMP-specific phosphodiesterase type 1 ( PDE1). By blocking this enzyme, Vinpocetine elevates the levels of the second messenger cyclic GMP in cerebral vascular smooth muscle cells. This molecular cascade ultimately leads to vasorelaxation of the blood vessels and selective cerebrovasodilation, which is the physiological basis for increasing cerebral blood flow (CBF).

Neuronal Membrane Stabilization and Metabolic Sparing

The second core domain involves the drug's interaction with the electrical signaling of nerve cells. Vinpocetine acts by blocking voltage-gated Na^+ channels, particularly in compromised neurons, which stabilizes the neuronal membrane and limits excessive Na^+ influx. This mechanism directly contributes to reducing the metabolic demand of the neuron, thereby conserving ATP content and modulating the cellular utilization of delivered oxygen and glucose.

Dosage and Administration Information

Cavinton (vinpocetine) is administered according to a regulated, two-phase protocol that utilizes different dosage forms and routes for initial and maintenance treatment. This approach is standardized in regulatory documentation and defines the precise manner in which the medicine must be taken.

Official Administration Protocol

Administration typically begins with the Intravenous (IV) route for an acute period, followed by a switch to the Oral (tablet) route for long-term maintenance. The concentrate for infusion requires dilution in a large volume of solution and must be administered via slow drip infusion.

Administration Detail	Official Guideline
Standard Oral Dose	5 mg tablet, taken three times a day (TID).
IV Starting Dose	20 mg once daily, administered as a slow infusion.
Maximum Dose	May be gradually increased up to 1 mg/kg body weight.
Timing	Oral tablets must be taken after a meal (with food) to ensure proper absorption.

Treatment Course and Population Rules

Regulatory instructions define a specific duration for the initial IV phase, which typically lasts 10 to 14 days. Following this period, the patient is transitioned to the oral tablet regimen. This transition requires the intravenous dose to be gradually reduced before discontinuation and the start of the maintenance phase.

For specific populations, official guidelines specify that no dosage adjustment is necessary for older adults. However, dose reduction is mandated in patients diagnosed with severe renal impairment. The medicine is not recommended for use in children or adolescents due to insufficient clinical data.

Recent Clinical Evidence

Recent Clinical Evidence (Vinpocetine)

Vinpocetine, the active substance in Cavinton, has been the subject of research concerning its use in the treatment of cerebrovascular disorders and cognitive decline. Clinical evidence is mixed, and its status varies significantly across global regulatory bodies.

Efficacy Studies

Research has explored the potential of vinpocetine in conditions affecting the brain and inner ear:

Dementia and Cognitive Impairment: Several trials have investigated the effects of vinpocetine in individuals with mild to moderate dementia. A Cochrane review noted that while some short-term studies suggested a potential for a small benefit in thinking skills, the available evidence from randomized controlled trials was deemed insufficient to make a definitive recommendation due to limitations in study size and duration.
Stroke: Studies have examined the effects of intravenous vinpocetine administration following acute ischemic stroke. Findings from some trials suggest that its use may coincide with observed changes in cerebral blood flow and certain markers of neurological function. However, meta-analyses suggest that the evidence remains inconclusive regarding its ability to reduce the risk of death or dependency in stroke survivors.

Safety and Tolerability

Vinpocetine is generally considered to be possibly safe for most people when used appropriately for up to one year. Common adverse effects reported in trials include stomach discomfort, headache, and dizziness.

Regulatory and Safety Warnings:

Area of Concern	Clinical Observation
Bleeding Risk	Research suggests vinpocetine may slow blood clotting and decrease platelet aggregation. Caution is advised for individuals using blood-thinning medications.
Pregnancy/Fetus	Regulatory warnings advise against its use during pregnancy or by those who may become pregnant, due to data suggesting potential adverse reproductive effects, including increased risk of miscarriage.

Frequently Asked Questions (FAQ)

Common questions about Cavinton (FAQ)

Q: What does 'vasodilator' mean in simple terms when talking about this drug?

Cavinton is classified as a cerebral vasodilator. This means its primary action is to cause the blood vessels in the brain to widen or relax. This mechanism is intended to support local blood flow within the brain tissue, enhancing the delivery of oxygen and glucose.

Q: Is Cavinton known to interact with common pain relievers like ibuprofen?

Official product information advises caution regarding use with other medicines classified as antiplatelet agents, a class that includes drugs like ibuprofen. The potential for additive pharmacodynamic effects exists with these agents, which may result in an increased risk of bruising or bleeding, according to regulatory data.

Q: Is Cavinton contraindicated for people with specific liver problems?

Regulatory documents indicate that caution is advised for people with hepatic impairment (liver problems). However, the medicine is generally not listed as being absolutely contraindicated for this patient group. Dosage adjustments are typically managed by a healthcare provider, particularly in patients with severe hepatic impairment.

Q: What is the connection between Cavinton and inner ear problems or vertigo?

Regulatory documents confirm that vertigo (a sensation of dizziness) is listed as an uncommon adverse effect of the medicine. Separately, the medicine's regulatory status in some regions encompasses use for certain symptoms associated with inner ear disorders.

Q: Have there been large-scale studies on the long-term safety of Cavinton?

Studies and official product information confirm safety data supporting use for up to one year. The oral tablet form is intended for long-term maintenance treatment, and use has been monitored based on the available clinical data.

Q: Is Cavinton considered a blood thinner, or does it work differently?

Cavinton works differently than a direct blood thinner. It is a cerebral vasodilator that acts by relaxing blood vessel walls to support blood flow in the brain. Regulatory documents note caution due to potential effects when used with antiplatelet agents.

Q: Are there specific food restrictions while taking Cavinton?

Regulatory documents do not list specific food groups or items that must be restricted while taking the medicine. However, the oral tablets must be taken after a meal to ensure the drug is properly absorbed into the body.

Q: Is there a maximum time frame for continuous use of Cavinton?

Official administration protocols define the tablet form as suitable for long-term maintenance treatment. Clinical studies have supported the continuous use and safety of the typical dosage for periods of 6 to 12 months.

Q: How long does it usually take to feel any effects from Cavinton?

According to official product information, the observation of activity usually begins to appear approximately after one week of continuous treatment. The maximum observation of effects is typically reached after about three months of use.

Q: Does Cavinton have a sedative or stimulating effect?

The medicine is not formally classified as a sedative or stimulant. However, official documents list some sleep disorders such as insomnia (difficulty sleeping) or somnolence (drowsiness) among its documented side effects.

Q: Is it okay to take Cavinton if I occasionally miss a dose?

Standard patient information leaflets typically describe guidance for missed doses, noting that a patient should never take a double dose to compensate. The leaflet usually advises how to proceed with the next scheduled dose.

Q: What are the official uses of Cavinton according to regulatory bodies?

The medicine is officially indicated in many countries for the treatment of cerebrovascular disorders. This includes certain symptoms of neurological or cognitive impairment associated with blood flow issues.

Q: What is the washout period for Cavinton before starting another similar medicine?

Regulatory data on pharmacokinetics is available, indicating the medicine has a short plasma elimination half-life of approximately 1.5 to 3 hours in humans. This pharmacokinetic data provides information regarding the drug's presence in the body over time.

Q: How is Cavinton eliminated from the body?

According to official documents, the medicine is rapidly metabolized in the liver. The resulting compounds are then eliminated from the body through both the urine and feces.

Q: What should I do if I think I'm experiencing a side effect from Cavinton?

Standard patient information leaflets typically advise that if a patient experiences any undesirable effects, even those not listed in the leaflet, they should consult their doctor or healthcare provider immediately.

Q: Does Cavinton affect vision or cause eye problems?

Official regulatory documents list vision-related adverse effects such as diplopia (double vision) and blurred vision. These are documented side effects associated with the medicine.

Q: Is Cavinton a controlled substance in any country?

The medicine is categorized as a prescription-only medicine in many countries. It is not generally listed as a scheduled narcotic or controlled substance by major international regulatory bodies.

How should Cavinton be stored and disposed of?

Storage and Disposal of Vinpocetine (Cavinton)

Storage and disposal requirements for vinpocetine preparations are strictly defined by regulatory labeling to maintain product quality and ensure safety.

Storage Requirements

All forms of the medicine must be kept out of the sight and reach of children. For the Concentrate for Solution for Infusion, storage must not exceed 25 C and the product must be protected from light. Any prepared solution for infusion must be used immediately and the unused portion discarded as stability is not maintained. Certain tablet formulations are labeled as requiring no special storage conditions.

Disposal Instructions

Expired or unused medication must not be disposed of via wastewater or household garbage. The product must be returned to an authorized pharmaceutical waste collection point (e.g., at a pharmacy) to ensure safe and environmentally compliant destruction.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.